Spyre Therapeutics, Inc. SYRE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s investing cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported investing cash flow of $56.58M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s investing cash flow increased by 92855.7% year-over-year, from -$61K to $56.58M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2022 to 2025), Spyre Therapeutics, Inc.'s investing cash flow has grown at a 58.6% compound annual growth rate (CAGR), from $57.01M to -$143.48M.
- What does investing cash flow mean?
- The net cash impact of buying and selling investments and physical assets.
- How do you interpret investing cash flow?
- Negative values typically indicate the purchase of securities to preserve cash, while positive values indicate the liquidation of assets to fund operations.
- How does investing cash flow compare across companies?
- Highly variable depending on the stage of the company's cash management cycle.